Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases

Stock Information for Revive Therapeutics Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Revive Therapeutics Ltd

Revive Therapeutics Announces Proposed Shares for Debt Settlement
Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio
Revive Therapeutics Reports Grant of Options
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
Revive Therapeutics Announces Proposed Private Placement
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.